Compare Adaptive Biotechnologies Corp (ADPT) vs Digital Realty Trust, Inc. (DLR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Digital Realty Trust, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.05 (market cap $3.33B), while Digital Realty Trust, Inc. trades at $175.36 (market cap $64.71B). The key difference: Digital Realty Trust, Inc. is far larger — about 19.4× Adaptive Biotechnologies Corp's market cap, and Digital Realty Trust, Inc. pays a 2.79% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DLR | |
|---|---|---|
Market Cap | $3.33B | $64.71B |
Sector | Health | Real Estate |
52-Week High | $22.37 | $203.91 |
52-Week Low | $10.24 | $147.93 |
Enterprise Value | $3.19B | $82.23B |
Dividend Yield | — | 2.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
DLR trades at $174.9, up 0.92% today, with a bearish technical signal but strong analyst buy consensus. The stock shows robust revenue growth, with 2025 revenue at $6.11B and net income margin of 21.73%, though valuation ratios like P/E of 46.07 appear elevated. Recent news highlights a $7.8B data center acquisition from Blackstone, expanding its hyperscale portfolio amid AI-driven demand.
Outlook remains positive with a consensus price target of $219.08, but risks include high debt levels, execution challenges from recent acquisitions, and competitive pressures. The stock offers growth exposure to data center infrastructure, supported by institutional confidence, yet investors should weigh valuation concerns against expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →
